Trial Profile
An Open, Multicenter, Phase Ib/II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection in Patients With Advanced Gastric/ Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Jul 2025
Price :
$35
*
At a glance
- Drugs Satricabtagene autoleucel (Primary) ; Docetaxel; Irinotecan; Nivolumab; Paclitaxel; Rivoceranib
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors CARsgen
Most Recent Events
- 25 Jun 2025 According to a CARsgen media release, based on data from this trial the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy.
- 01 Jun 2025 According to a CARsgen media release, company announces that the results of the pivotal Phase II clinical trial in China have been published in The Lancet and were orally presented at the 2025 ASCO Annual Meeting.
- 28 May 2025 According to a CARsgen media release, company announces that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Priority Review to satricabtagene autoleucel ("satri-cel", CT041)(an autologous CAR T-cell product candidate against protein Claudin18.2), for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy.